A specialty pharmacy benefits coordinator who has worked only with commercial payer PA processes and then moves to a pharmacy with significant Medicaid volume will encounter a process that feels structurally different — not just in its timelines, but in its underlying logic, documentation requirements, and administrative infrastructure. The reverse is equally true. The frameworks aren't variants of the same system; they reflect genuinely different program structures, funding mechanisms, and regulatory environments.
Understanding those differences isn't just academic. Submitting a Medicaid PA with commercial-program assumptions about what documentation is needed, what the response timeline will be, or how appeals work is one of the more reliable ways to create delays that should have been avoidable.
The Structural Difference: Who Sets the Rules
For commercial payers, prior authorization criteria are set by the insurer's medical policy team — typically informed by clinical guidelines, formulary design, and rebate arrangements with manufacturers. A commercial insurer's PA criteria for a specific drug may change annually with formulary updates, and different plans within the same parent company may have different criteria for the same drug.
For Medicaid, the structure is more layered. The federal-state partnership means that CMS sets broad requirements under 42 CFR Part 438 and related regulations, but states administer their programs with significant latitude in how they structure PA requirements. Many states operate their Medicaid pharmacy benefit through managed care organizations (MCOs) under contract — which means the PA criteria for a Medicaid patient may actually be set by the MCO, not the state agency directly.
The practical implication: a specialty pharmacy serving Medicaid patients in Massachusetts, Connecticut, and Rhode Island is dealing with three different state programs, each potentially operating through multiple MCO contractors, each with their own PA criteria, portals, and response timelines. The drug coverage rules that apply to an MCO enrollee are determined by that MCO's contract with the state, subject to state plan requirements — a policy stack that can be challenging to navigate without systematic tracking of which MCO covers which patients and what each MCO's requirements are for specific drugs.
PA Response Timeline Differences
Commercial payers operate under state insurance regulations that typically mandate PA response timelines — most states require standard PA decisions within a specified period (commonly 3–5 business days) and expedited decisions within 24–72 hours for urgent requests. Federal rules under the ACA and subsequent CMS regulations have added timeline requirements for qualified health plans as well.
Medicaid timelines are governed by separate regulatory frameworks. Under 42 CFR 438.210, Medicaid MCOs are required to make standard PA decisions within 14 calendar days (with a possible 14-day extension), and expedited decisions within 72 hours. That 14-day standard window is significantly longer than most commercial payer standard timelines — and it applies to MCOs, not fee-for-service Medicaid, which may have its own timeline rules under state policy.
For a specialty pharmacy whose workflow treats all PA submissions as equivalent, the difference between a 3-day commercial response and a 14-day Medicaid response is not just a performance expectation gap — it's a patient communication and workflow planning issue. Patients on Medicaid need to understand at intake that their PA timeline may be substantially longer than a neighbor with commercial insurance.
We're not saying Medicaid PA processes are worse than commercial — the regulatory frameworks reflect different program structures and funding constraints, not different levels of care for the patients involved. We're saying that operating them with the same workflow assumptions is a setup for surprises that can be avoided with payer-type-specific processes.
Formulary and Preferred Drug List Dynamics
Commercial payers use formularies — tiered drug lists that determine coverage levels and PA requirements — that are updated on annual contract cycles and can be mid-year modified in some plans. PA requirements for a given drug typically track its formulary tier: non-preferred or non-formulary drugs face stricter PA criteria than preferred alternatives.
Medicaid programs use Preferred Drug Lists (PDLs), which serve a similar function but are structured differently. State Medicaid PDLs are developed through a separate clinical and supplemental rebate process. Under the Medicaid Drug Rebate Program (MDRP), manufacturers pay rebates to states for covered outpatient drugs, and states can negotiate additional supplemental rebates that influence PDL placement. Drugs that are on a state's PDL may have different PA requirements than non-PDL drugs, and PDL status can differ from state to state for the same medication.
For specialty pharmacies, this matters most for biologics and other high-cost specialty drugs where PDL status is actively contested through rebate negotiations. A drug that receives preferred coverage in one state's Medicaid program may require PA in another state's program — not because the clinical criteria differ, but because the rebate arrangement did.
Step Therapy: Common to Both, Structured Differently
Step therapy requirements appear in both commercial and Medicaid programs, but their structure and enforceability differ. Commercial payer step therapy is typically set in the plan's benefit design and can be challenged through an exception process when the prescriber documents clinical reasons why step therapy is inappropriate for the specific patient.
Several states have enacted step therapy reform laws that establish explicit rights for patients and prescribers to obtain exceptions from step therapy requirements. These laws vary by state and may apply differently to commercial fully insured plans, self-insured ERISA plans, and Medicaid managed care — meaning that a step therapy exception right that exists for a commercially insured patient in a given state may not apply to a Medicaid enrollee in the same state in the same way.
For specialty pharmacies, knowing which state's step therapy exception law applies to which patients and which plan types — and what documentation the exception process requires — is operational knowledge that belongs in a payer-tracking system, not in a single coordinator's memory.
Appeals: Different Processes, Different Forums
| Process aspect | Commercial | Medicaid MCO |
|---|---|---|
| First-level appeal | Internal appeal to payer | MCO internal grievance/appeal |
| External appeal | Independent review organization (IRO) — state-mandated | State fair hearing or state agency review |
| Timeline to file appeal | Plan-specific, typically 60–180 days | State-regulated, typically 30–90 days from denial notice |
| Peer-to-peer review availability | Most commercial plans offer P2P review | MCO-dependent; not universally available |
The external appeal mechanism is structurally different between commercial and Medicaid programs. Commercial plan external appeals go to an Independent Review Organization (IRO) — a third-party clinical reviewer contracted with the state insurance commissioner. Medicaid denials, after exhausting MCO-level appeals, typically enter the state fair hearing process through the state Medicaid agency — a different forum with different evidence standards and decision timelines.
Medicare Part D: The Third Category
For completeness: Medicare Part D prescription drug plans constitute a third payer category with its own PA structure. Part D PA criteria are set by plan sponsors within CMS guidelines, and appeals for Part D coverage determinations follow the Part D appeals process — escalating from plan redetermination to independent review entity (IRE) to Administrative Law Judge (ALJ) hearing. The Part D exception and appeals process is distinct from both commercial and Medicaid processes, and specialty pharmacies serving a significant Medicare population benefit from having Part D-specific workflow documentation.
The common thread across all three payer types is that PA is easier — and faster — when the pharmacy's workflow reflects the actual rules of each payer category rather than treating all PAs as variations of a single process. The heterogeneity is a permanent feature of the US payer landscape, and the specialty pharmacies that navigate it most effectively are the ones that have stopped trying to run a single workflow for all payer types.
